Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Legal Proceedings - A class action lawsuit has been filed against MoonLake, alleging that the company misled investors regarding the trial design and efficacy data of SLK prior to the announcement of the trial results [1][2][3]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [3]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy being substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, representing a 90% decrease, which analysts described as a "worst case outcome" [2][6]. Product Comparison - SLK's commercial prospects were heavily reliant on demonstrating efficacy comparable to or superior to BIMZELX, which is already FDA-approved for the same indication [4]. - The lawsuit claims that MoonLake made false statements regarding the advantages of SLK's Nanobody structure over traditional monoclonal antibodies, asserting that it would lead to superior clinical benefits [5]. Investor Communication - Throughout the class period, MoonLake promoted SLK's structural advantages, claiming it could achieve benefits unattainable by monoclonal antibodies and positioned it as a potential "gold standard" treatment [5]. - The lawsuit alleges that these statements were misleading and that the company failed to disclose critical information about SLK's clinical efficacy [5][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quanex Building Products Corporation during the specified Class Period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Quanex securities between December 12, 2024, and September 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lawsuit alleges that Quanex made false and misleading statements regarding its operations and the condition of its equipment, which led to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of WPP plc, covering the period from February 27, 2025, to July 8, 2025, due to alleged misleading statements regarding the company's media arm [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased WPP plc ADSs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - Investors wishing to serve as lead plaintiffs must file their motion by December 8, 2025 [1][3]. Group 2: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm, which was reportedly unprepared for macroeconomic challenges and losing market share to competitors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against KinderCare Learning Companies, Inc. alleging misleading statements during its October 2024 IPO, claiming that the company concealed a history of safety and care failures from investors [1][5]. Financial Performance - Since the IPO, KinderCare's stock has significantly declined from an offering price of $24 per share to lows near $9 per share, attributed to the market's realization of the company's unfounded positive statements [3]. Revenue Sources - More than 30% of KinderCare's revenues are derived from federal subsidies, making the alleged omissions regarding safety and care failures particularly significant, as they expose the company to undisclosed legal and regulatory risks [2]. Legal Investigation - Hagens Berman is investigating the claims against KinderCare, focusing on the alleged concealment of safety and care failures that may have led to an artificially inflated IPO price and subsequent investor losses [4][5]. Investor Communication - The firm encourages investors who purchased KLC stock in the IPO and suffered losses to consider their legal options, emphasizing the disconnect between KinderCare's presentation and the alleged reality of its operations [4][5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities, alleging that the company failed to disclose material adverse facts during the Class Period from February 5, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare did not disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced, misleading investors about the company's business prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Cytokinetics, Inc. common stock between December 27, 2023, and May 6, 2025, of the upcoming lead plaintiff deadline on November 17, 2025, for a class action lawsuit related to misleading statements about the company's drug approval process [1][5]. Group 1: Class Action Details - Investors who bought Cytokinetics common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm or through their website [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the New Drug Application (NDA) submission and approval for aficamten, which misled investors about the regulatory process [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - The investigation follows a significant stock price drop of 51.5% on August 5, 2025, after Agilon Health suspended its full-year 2025 financial guidance, citing more acute industry headwinds than previously expected [3]. Group 2: Company Performance and Financial Guidance - On August 4, 2025, Agilon Health reported its second-quarter results and indicated that it was suspending its previously issued financial guidance for the full year 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. for allegedly disseminating false and misleading statements regarding the efficacy of its drug Efzofitimod during a clinical trial [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, with a lead plaintiff deadline set for December 8, 2025 [1][6]. - The complaint claims that aTyr Pharma concealed material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [3]. Group 2: Clinical Trial Results - aTyr Pharma conducted a Phase 3 study (EFZO-FIT) to evaluate Efzofitimod's safety and efficacy in patients with pulmonary sarcoidosis [3]. - On September 15, 2025, aTyr Pharma announced that the EFZO-FIT study failed to meet its primary endpoint regarding the reduction of mean daily oral corticosteroid dose at week 48 [4]. Group 3: Stock Price Impact - Following the announcement of the disappointing trial results, aTyr Pharma's stock price plummeted by 83.2%, dropping from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025 [5]. Group 4: Legal Representation - Investors affected by the stock price decline are encouraged to contact Shamis & Gentile, P.A. for information on seeking recovery claims [2][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RCI Hospitality Holdings, Inc. between December 15, 2021, and September 16, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased RCI Hospitality securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is November 20, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements, engaged in tax fraud, and committed bribery to cover up the fraud [5]. - It is claimed that these actions resulted in an understatement of the legal risks facing RCI Hospitality, leading to misleading statements about the company's business and operations [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of KinderCare Learning Companies, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's October 2024 IPO [1] Group 1: Class Action Details - Investors who purchased KinderCare common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 14, 2025 [3] - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, and that the company did not meet minimum care standards [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for its securities class action settlements [4]